Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erlenbach am Main – page 32

985 clinical trials in Erlenbach am Main, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erlenbach am Main at a glance
985
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

985 trials in Erlenbach am Main

Open in trial search

Cardiovascular disorder+3

Not yet recruiting

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Hypercholesterolaemia

Not yet recruiting

Effect of laroprovstat/rosuvastatin combination versus laroprovstat, rosuvastatin, and placebo on LDL‑C in hypercholesterolemia patients not previously treated with lipid‑lowering therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:EXPD-101
  • Sponsor:Expedition Therapeutics Inc.

Psoriasis

Not yet recruiting

Long-term Safety and Efficacy of ORKA-001 in Adults with Moderate-to-Severe Plaque Psoriasis (Open-Label Extension Study)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ORKA-001
  • Sponsor:Oruka Therapeutics Inc.

Dermatitis atopic

Not yet recruiting

A Phase 2b Study Evaluating the Efficacy and Safety of ENV-294 in Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ENV-294
  • Sponsor:Enveda Therapeutics Inc.

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus

Not yet recruiting

Efficacy and Safety of Alogliptin Plus Empagliflozin Compared with Alogliptin Alone or Empagliflozin Alone in Adults with Type 2 Diabetes on Metformin

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alogliptin
  • Sponsor:Tecnimede-Sociedade Tecnico-Medicinal S.A.

Acne

Not yet recruiting

Safety and Efficacy Study of the Acne mRNA vaccine (mrt1800, mrt1801, mrt1802) in Adults 18‑45 Years with Moderate to Severe Acne

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:MRT1800
  • Sponsor:Sanofi Pasteur Inc.

Asthma

Not yet recruiting

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Chiesi Farmaceutici S.p.A.

Dermatitis atopic+1

Not yet recruiting

Long-Term Safety and Efficacy of Lebrikizumab in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Lebrikizumab
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erlenbach am Main

What the registry says about research in the country

01 Rheumatology Research

Clinical investigations focusing on acute gout management are evaluating different treatment approaches in primary care settings. The research aims to compare the effectiveness of traditional and alternative therapeutic options for managing severe gout attacks.

  • Acute Gout Treatment
  • Pain Management Assessment
  • Primary Care Interventions

These trials utilize advanced pain measurement techniques to evaluate treatment outcomes, contributing to better understanding of inflammatory arthritis management in clinical practice.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.